Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Overview
- Enzymes and metabolites in MFAO (1)
- Enzymes and metabolites in MFAO (2)
- Enzymes and metabolites in MFAO (3)
- Discovery rate of MFAO deficiencies (1)
- Elucidation sequence for MCAD deficiency
- Discovery rate of MFAO deficiencies (2)
- Strategy of investigation (1)
- Analysis of organic acid in urine
- MCAD deficiency indicated
- Strategy of investigation (2)
- Neonatal screening of fatty acid oxidation defects
- Strategy of investigation (3)
- Fatty acid oxidation genes with defects (1)
- Disease-associated gene variations
- Effect of gene variations
- Mitochondrial protein quality control system
- Expression of MCAD variant proteins
- Expression of MCAD activity in variant proteins
- Structure of MCAD monomeric molecule
- Expression of variant proteins
- Disease-associated gene variations
- Prevalence of MCAD 985A >G
- Frequency of MCAD 985A > G
- Diagnostic strategy for MCAD deficiency
- Fatty acid oxidation genes with defects (2)
- Conclusion
- Thank you for your attention
Topics Covered
- Mitochondrial fatty acid oxidation (FAO) defects
- FAO biochemical pathways
- FAO defects
- Diagnosis of FAO defects
- Newborn screening for FAO defects, especially medium-chain acyl-CoA dehydrogenase (MCAD) deficiency
- Diagnostic genetic analysis for MCAD gene variations
- Expression studies of variant MCAD proteins in E.coli
- Protein misfolding as a pathogenic mechanism in MCAD deficiency
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Gregersen, N. (2015, September 8). Mitochondrial fatty acid oxidation deficiencies [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/POJK7232.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Niels Gregersen has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
Mitochondrial Fatty Acid Oxidation Deficiencies.
0:06
In this lecture, I will start by describing
the biochemistry of mitochondrial fatty acid metabolism.
I will then talk about the fatty acid beta-oxidation deficiencies.
I will discuss the diagnostic strategies for their detection.
I will then use some time on the molecular genetics and molecular pathogenesis.
There after, I will mention the concept of
prevalent mutations and their use in the diagnostic procedure.
And finally, I will end up with some conclusions.
0:43
Now, let us look at the metabolites and enzymes of the fatty acid metabolism.
Fatty acids liberated from fat and foodstuff of
fatty foods are transported through the plasma membrane.
This transport is facilitated by the fatty acids transport protein.
The fatty acids are activated to the coenzyme-A derivative,
by means of fatty Acyl-CoA synthetase,
which is associated with the mitochondrial outer membrane.
To further metabolize the fatty acids, carnitine is necessary.
Carnitine is taken up through the carnitine transporter.
Carnitine is used as substrate to kill
the fatty Acyl-CoA for Carnitine palmitoyl-CoA transferase I.
The product is fatty Acyl carnitine,
which is located in the inter-membrane space of the mitochondria.
The fatty acyl carnitine is transported through
the inner-membrane and this is facilitated by carnitine/acylcarnitine translocase.
Now the fatty acids are inside the mitochondria but to be metabolized,
it has to be converted back to the acyl coenzyme-A derivative.